The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% Friday, halting the momentum the stock generated just a day earlier after ...

Sarepta Therapeutics announced late Friday evening that it will not comply with the Food and Drug Administration's ...

Drugmaker Sarepta Therapeutics says it won't comply with a request from U.S. regulators to halt all shipments of its gene ...

Sarepta Therapeutics refuses the FDA request to halt its gene therapy shipments following a third patient death, challenging ...

In a highly unusual move, Cambridge-based Sarepta said late Friday won’t comply with a request from the Food and Drug ...

Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.

Thereafter, on June 15, 2025, Sarepta disclosed that a second patient had died of acute liver failure following treatment with ELEVIDYS, leading to Sarepta suspending shipment of ELEVIDYS for ...

Thereafter, on June 15, 2025, Sarepta disclosed that a second patient had died of acute liver failure following treatment with ELEVIDYS, leading to Sarepta suspending shipment of ELEVIDYS for non ...

On June 15, 2025, the Company disclosed that a second patient had died of acute liver failure following treatment with ELEVIDYS, leading to Sarepta suspending shipment of ELEVIDYS for non ...

Like the first death reported in March, Sarepta Therapeutics attributed the fatality to a case of acute liver failure following dosing of the Duchenne muscular dystrophy gene therapy, Elevidys ...

Sarepta Therapeutics shares sank to their lowest level in nine years Monday after a second patient taking its Elevidys drug died.